Nature Search

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

Dickkopf-related protein 1 (DKK1) is a secreted protein associated with poorer outcomes in patients with gastric cancer. Here, the authors report part B of the DisTinGuish phase II trial reporting the safety and efficacy of DKN-01 (DKK1 neutralising antibody) in combination with tislelizumab (anti-PD-1) in patients with advanced gastric/gastoesophageal junction cancer and elevated DKK1 expression.

Keun-Wook Lee
Devalingam Mahalingam
Samuel J. Klempner
ResearchOpen Access10 Jul 2025
Nature Communications

Volume: 16, P: 1-8
First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Mahalingam et al. report findings from a first-in-human dose escalation study of the tumor microenvironment modulator VT1021 in patients with advanced solid tumors. VT1021 is found to be safe and well tolerated and the recommended phase II dose is established based on pharmacokinetic/dynamic properties and preliminary clinical activities.

Devalingam Mahalingam
Wael Harb
Jing Watnick
ResearchOpen Access13 Jan 2024
Communications Medicine

Volume: 4, P: 1-12
Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)

Devalingam Mahalingam
Siqi Chen
Bin Zhang
Research13 Jul 2023
British Journal of Cancer

Volume: 129, P: 782-790
Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Chen et al. report findings from a phase 1 dose expansion study of the tumor microenvironment modulator VT1021 in patients with solid tumors. VT1021 is found to be safe and tolerable, with preliminary evidence of efficacy and biomarkers of response.

Jian Jenny Chen
Melanie Y. Vincent
Jing Watnick
ResearchOpen Access21 May 2024
Communications Medicine

Volume: 4, P: 1-15
Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

Sukeshi Patel Arora
Laura Tenner
Devalingam Mahalingam
Research23 Jun 2022
British Journal of Cancer

Volume: 127, P: 1153-1161

Quick links

Search

Filter By:

DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B

First-in-human phase I dose escalation trial of the first-in-class tumor microenvironment modulator VT1021 in advanced solid tumors

Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)

Phase 1 dose expansion and biomarker study assessing first-in-class tumor microenvironment modulator VT1021 in patients with advanced solid tumors

Modulation of autophagy: a Phase II study of vorinostat plus hydroxychloroquine versus regorafenib in chemotherapy-refractory metastatic colorectal cancer (mCRC)

Search

Quick links